

reach a preliminary determination in antidumping and countervailing duty investigations in 45 days, or in this case by February 14, 2014. The Commission's views must be transmitted to Commerce within five business days thereafter, or by February 24, 2014.

DATES: Effective December 31, 2013.

FOR FURTHER INFORMATION CONTACT:

Chris Cassise (202-708-5408), Office of Investigations, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202-205-2000. General information concerning the Commission may also be obtained by accessing its internet server (<http://www.usitc.gov>). The public record for these investigations may be viewed on the Commission's electronic docket (EDIS) at <http://edis.usitc.gov>.

SUPPLEMENTARY INFORMATION: For further information concerning the conduct of these investigations and rules of general application, consult the Commission's Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A and B (19 CFR part 207).

Background.—These investigations are being instituted in response to a petition filed on December 31, 2013, by SolarWorld America Industries, Inc., Hillsboro, OR.

Participation in the investigations and public service list.—Persons (other than petitioners) wishing to participate in the investigations as parties must file an entry of appearance with the Secretary to the Commission, as provided in sections 201.11 and 207.10 of the Commission's rules, not later than seven days after publication of this notice in the **Federal Register**. Industrial users and (if the merchandise under investigation is sold at the retail level) representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to these investigations upon the expiration of the period for filing entries of appearance.

Limited disclosure of business proprietary information (BPI) under an administrative protective order (APO) and BPI service list.—Pursuant to

section 207.7(a) of the Commission's rules, the Secretary will make BPI gathered in these investigations available to authorized applicants representing interested parties (as defined in 19 U.S.C. 1677(9)) who are parties to the investigations under the APO issued in the investigations, provided that the application is made not later than seven days after the publication of this notice in the **Federal Register**. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.

Conference.—The Commission's Director of Investigations has scheduled a conference in connection with these investigations for 9:30 a.m. on January 21, 2014, at the U.S. International Trade Commission Building, 500 E Street SW., Washington, DC. Requests to appear at the conference should be emailed to William.bishop@usitc.gov and Sharon.bellamy@usitc.gov (DO NOT FILE ON EDIS) on or before January 16, 2014. Parties in support of the imposition of countervailing and antidumping duties in these investigations and parties in opposition to the imposition of such duties will each be collectively allocated one hour within which to make an oral presentation at the conference. A nonparty who has testimony that may aid the Commission's deliberations may request permission to present a short statement at the conference.

Written submissions.—As provided in sections 201.8 and 207.15 of the Commission's rules, any person may submit to the Commission on or before January 24, 2014, a written brief containing information and arguments pertinent to the subject matter of the investigations. Parties may file written testimony in connection with their presentation at the conference no later than three days before the conference. If briefs or written testimony contain BPI, they must conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission's rules. Please consult the Commission's rules, as amended, 76 FR 61937 (Oct. 6, 2011) and the Commission's Handbook on Filing Procedures, 76 FR 62092 (Oct. 6, 2011), available on the Commission's Web site at <http://edis.usitc.gov>.

In accordance with sections 201.16(c) and 207.3 of the rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.12 of the Commission's rules.

Issued: January 3, 2014.

By order of the Commission.

William R. Bishop,

Supervisory Hearings and Information Officer.

[FR Doc. 2014-00130 Filed 1-7-14; 8:45 am]

BILLING CODE 7020-02-P

JUDICIAL CONFERENCE OF THE UNITED STATES

Hearings of the Judicial Conference Advisory Committee on Rules of Bankruptcy Procedure; *Federal Register* Citation of Previous Announcement: 78 FR 49768.

AGENCY: Judicial Conference of the United States, Advisory Committee on Rules of Bankruptcy Procedure.

ACTION: Notice of Cancellation of Open Hearing.

SUMMARY: The following public hearing on proposed amendments to the Federal Rules of Bankruptcy Procedure has been canceled: Bankruptcy Rules Hearing, January 31, 2014, Washington, DC

FOR FURTHER INFORMATION CONTACT: Jonathan C. Rose, Secretary and Chief Rules Officer, Rules Committee Support Office, Administrative Office of the United States Courts, Washington, DC 20544, telephone (202) 502-1820.

Dated: January 3, 2014.

Jonathan C. Rose,

Secretary and Chief Rules Officer.

[FR Doc. 2014-00112 Filed 1-7-14; 8:45 am]

BILLING CODE 2210-55-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration; Cerilliant Corporation

By Notice dated September 9, 2013, and published in the **Federal Register** on September 17, 2013, 78 FR 57176, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235)	I

Drug	Schedule	Drug	Schedule
Methcathinone (1237)	I	Oxycodone (9143)	II
Mephedrone (1248)	I	Hydromorphone (9150)	II
N-Ethylamphetamine (1475)	I	Ecgonine (9180)	II
N,N-Dimethylamphetamine (1480)	I	Ethylmorphine (9190)	II
Fenethylamine (1503)	I	Meperidine (9230)	II
Gamma Hydroxybutyric Acid (2010)	I	Methadone (9250)	II
JWH-018 (7118)	I	Dextropropoxyphene, bulk (9273)	II
JWH-073 (7173)	I	Morphine (9300)	II
JWH-200 (7200)	I	Oripavine (9330)	II
Alpha-ethyltryptamine (7249)	I	Thebaine (9333)	II
lBogaine (7260)	I	Levo-alphaacetyl/methadol (9648) ..	II
CP-47497 (7297)	I	Oxymorphone (9652)	II
CP-47497 C8 Homologue (7298)	I	Poppy Straw Concentrate (9670)	II
Lysergic acid diethylamide (7315)	I	Alfentanil (9737)	II
2C-T-7 (7348)	I	Sufentanil (9740)	II
Marihuana (7360)	I	Fentanyl (9801)	II
Tetrahydrocannabinols (7370)	I		
Mescaline (7381)	I		
3,4,5-Trimethoxyamphetamine (7390)	I		
4-Bromo-2,5-dimethoxyamphetamine (7391)	I		
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I		
4-Methyl-2,5-dimethoxyamphetamine (7395)	I		
2,5-Dimethoxyamphetamine (7396)	I		
3,4-Methylenedioxyamphetamine (7400)	I		
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I		
3,4-Methylenedioxymethamphetamine (7405)	I		
4-Methoxyamphetamine (7411)	I		
5-Methoxy-N,N-dimethyltryptamine (7431)	I		
Alpha-methyltryptamine (7432)	I		
Diethyltryptamine (7434)	I		
Dimethyltryptamine (7435)	I		
Psilocybin (7437)	I		
Psilocyn (7438)	I		
5-Methoxy-N,N-diisopropyltryptamine (7439)	I		
N-Benzylpiperazine (7493)	I		
MDPV (7535)	I		
Methylone (7540)	I		
Desomorphine (9055)	I		
Etorphine (except HCl)(9056)	I		
Heroin (9200)	I		
Morphine-N-oxide (9307)	I		
Normorphine (9313)	I		
Pholcodine (9314)	I		
Dextromoramide (9613)	I		
Dipipanone (9622)	I		
Racemoramide (9645)	I		
Trimeperidine (9646)	I		
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)	I		
Tilidine (9750)	I		
Amphetamine (1100)	II		
Methamphetamine (1105)	II		
Methylphenidate (1724)	II		
Amobarbital (2125)	II		
Pentobarbital (2270)	II		
Secobarbital (2315)	II		
Phencyclidine (7471)	II		
Phenylacetone (8501)	II		
Cocaine (9041)	II		
Codeine (9050)	II		
Dihydrocodeine (9120)	II		

The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinol. No other activities for these drug codes are authorized for this registration.

Comments and requests for hearings on applications to import narcotic raw material are not appropriate. 72 FR 3417(2007)

DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Cerilliant Corporation to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: December 23, 2013.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014-00057 Filed 1-7-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application; Noramco, Inc. (GA)

Pursuant to 21 CFR 1301.33(a), this is notice that on July 4, 2013, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Gamma Hydroxybutyric Acid (2010)	I
Dihydromorphone (9145)	I
Morphine-N-oxide (9307)	I
Codeine-N-oxide (9053)	I
Amphetamine (1100)	II
Methylphenidate (1724)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Oripavine (9330)	II
Thebaine (9333)	II
Opium tincture (9630)	II
Oxymorphone (9652)	II
Noroxymorphone (9668)	II
Alfentanil (9737)	II
Remifentanil (9739)	II
Sufentanil (9740)	II
Carfentanil (9743)	II
Tapentadol (9780)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than March 10, 2014.

Dated: December 23, 2013.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2014-00054 Filed 1-7-14; 8:45 am]

BILLING CODE 4410-09-P